Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
$5.04
-14.0%
$5.51
$2.43
$46.68
$15.25M1.15643,263 shs295,670 shs
Graphite Bio, Inc. stock logo
GRPH
Graphite Bio
$13.89
$2.01
$4.26
$185.20M0.2282,405 shs435,164 shs
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
$1.71
$1.79
$1.12
$4.20
$127.13M0.9195,163 shs81,201 shs
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
$3.64
-4.5%
$3.28
$1.11
$5.17
$489.85M2.392.51 million shs2.37 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
-13.99%-12.50%-26.57%+2.44%-73.42%
Graphite Bio, Inc. stock logo
GRPH
Graphite Bio
0.00%0.00%0.00%0.00%0.00%
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
0.00%+10.32%-5.00%-14.93%+31.54%
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
-4.46%-1.09%-15.15%+128.93%-11.44%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
0.7702 of 5 stars
0.04.00.00.02.50.00.6
Graphite Bio, Inc. stock logo
GRPH
Graphite Bio
N/AN/AN/AN/AN/AN/AN/AN/A
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
1.7512 of 5 stars
3.32.00.00.01.10.01.3
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
3.6896 of 5 stars
4.41.00.00.02.35.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
0.00
N/AN/AN/A
Graphite Bio, Inc. stock logo
GRPH
Graphite Bio
0.00
N/AN/AN/A
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
2.50
Moderate Buy$6.50280.12% Upside
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
2.75
Moderate Buy$8.92144.96% Upside

Current Analyst Ratings Breakdown

Latest GRPH, PRME, CLDI, and IKT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/8/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $10.00
7/16/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$8.00
5/27/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$10.00 ➝ $1.50
5/20/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $6.00
5/20/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
5/20/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Neutral
5/19/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $12.00
(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
N/AN/AN/AN/A($2.32) per shareN/A
Graphite Bio, Inc. stock logo
GRPH
Graphite Bio
N/AN/AN/AN/A$3.15 per shareN/A
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
N/AN/AN/AN/A$1.78 per shareN/A
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
$4.96M98.74N/AN/A$1.37 per share2.66
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
-$29.22MN/A0.00N/AN/AN/AN/A-344.45%N/A
Graphite Bio, Inc. stock logo
GRPH
Graphite Bio
-$124.65M-$2.23N/AN/AN/AN/A-33.12%-27.96%N/A
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/A
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
-$198.13M-$1.56N/AN/AN/AN/A-107.87%-74.97%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
N/AN/AN/AN/AN/A
Graphite Bio, Inc. stock logo
GRPH
Graphite Bio
N/AN/AN/AN/AN/A
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
N/AN/AN/AN/AN/A
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
$1.4539.73%N/AN/A N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
N/A
0.19
0.19
Graphite Bio, Inc. stock logo
GRPH
Graphite Bio
N/A
39.20
39.20
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
N/A
0.85
0.85
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
N/A
6.50
6.50

Institutional Ownership

CompanyInstitutional Ownership
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
12.53%
Graphite Bio, Inc. stock logo
GRPH
Graphite Bio
54.32%
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
3.81%
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
70.37%

Insider Ownership

CompanyInsider Ownership
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
6.70%
Graphite Bio, Inc. stock logo
GRPH
Graphite Bio
38.40%
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
7.30%
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
22.74%
CompanyEmployeesShares OutstandingFree FloatOptionable
Calidi Biotherapeutics, Inc. stock logo
CLDI
Calidi Biotherapeutics
383.03 million20.04 millionN/A
Graphite Bio, Inc. stock logo
GRPH
Graphite Bio
658.24 million35.87 millionNot Optionable
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
674.34 million66.18 millionNot Optionable
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
234134.57 million100.38 millionOptionable

Recent News About These Companies

PRME Revenue Misses by 73%
Prime Medicine Holds Special Stockholder Meeting
Prime Medicine Halts Sales Agreement Prospectus
Prime Medicine Announces Pricing of Public Offering

New MarketBeat Followers Over Time

Media Sentiment Over Time

Calidi Biotherapeutics stock logo

Calidi Biotherapeutics NYSE:CLDI

$5.04 -0.82 (-13.99%)
Closing price 08/14/2025 04:00 PM Eastern
Extended Trading
$5.30 +0.27 (+5.26%)
As of 04:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.

Graphite Bio stock logo

Graphite Bio NASDAQ:GRPH

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. The company offers GPH102 for the treatment of beta-thalassemia; and GPH201 for the treatment of XSCID, a life-threatening disease for multiple mutations in a single gene. It also offers GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is based in South San Francisco, California.

Inhibikase Therapeutics stock logo

Inhibikase Therapeutics NYSE:IKT

$1.71 0.00 (0.00%)
Closing price 08/14/2025 04:00 PM Eastern
Extended Trading
$1.72 +0.01 (+0.58%)
As of 08/14/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Prime Medicine stock logo

Prime Medicine NYSE:PRME

$3.64 -0.17 (-4.46%)
Closing price 08/14/2025 04:00 PM Eastern
Extended Trading
$3.66 +0.01 (+0.41%)
As of 08/14/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.